Diabetes

January 3, 2018

Vitamin-based therapy for Metabolic diseases: A pharmaceutical mixture [PMFA] encompassing Pyridoxamine(PM) and Folic acid (FA) increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, incrases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 3/January/2017, 9.43 am

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June […]
January 3, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM:Docosahexaenoic acid (DHA) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 3/January/2017, 9.34 am

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
January 1, 2018

Vitamin-based regenerative therapy for reversing diabetes: A pharmaceutical mixture encompassing  Pyridoxamine, Calcitriol, Folic acid, and Ascorbic acid (PMCFAAA) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 1/January/2018, 4.20 pm

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, […]
December 30, 2017

Vitamin B-based therapy for TIIDM and obesity-associated metabolic deficits: A therapeutic mix (PMFA) encompassing Pyridoxamine (PM) and Folic acid (FA) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 30/December/2017, 11.21 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]